000			05539nam a22003975i 4500
001			86569
003			ES-MaUEC
005			20230207040604.0
007			cr nn 008mamaa
008			160524s2016 ja | s |||| 0|eng d
020			_a9784431555520
040			_aES-MaUEC
050		4	_aRC280.B8 _b2016 EB
082	0	4	_a616.994
245	1	0	_aPersonalized Treatment of Breast Cancer _cedited by Masakazu Toi, Eric Winer, John Benson, Suzanne Klimberg
264		1	_aTokyo _bSpringer Japan _c2016
300			_a1 recurso en línea (IX, 388 páginas) _b71 ilustraciones, 52 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aPart I Treatment for the Patients Having Breast Cancer High-Risk -- Chapter I Risk-Reducing Surgery for Breast Cancer Patients with BRCA Mutations -- Chapter 2 Prophylactic Risk Reducing Surgery for Breast Cancer -- Chapter 3 Merits and Demerits of Practice for Hereditary Breast and Ovarian Cancer Syndrome (Advices and Issues) -- Part II Axillary Treatment -- Chapter 4 Sentinel Lymph Node Biopsy and Neoadjuvant Chemotherapy in Breast Cancer Patients -- Chapter 5 Axillary Reverse Mapping (ARM) as a Means to Reduce Lymphedema During Sentinel Lymph Node or Axillary Node Dissection -- Chapter 6 Ultrasound for Axillary Staging -- Chapter 7 One Step Nucleic Acid Amplification(OSNA)Assay for Primary Breast Cancer -- Chapter 8 Management of the Clinically Node-Negative Axilla in Primary Breast Cancer -- Chapter 9 Lymphatic Mapping and Optimization of Sentinel Lymph Node Dissection -- Part III Radiation therapy -- Chapter 10 Personalization of Radiotherapy for Breast Cancer -- Chapter 11 New Technologies in Radiation Therapy -- Chapter 12 Radiotherapy Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer -- Part IV Preoperative Hormone Therapy -- Chapter 13 Novel Translational Research of Neoadjuvant Endocrine Therapy -- Chapter 14 Alterations of Biomarkers by Neoadjuvant Endocrine Therapy -- Part V Preoperative chemotherapy -- Chapter 15 Essence of Neoadjuvant Therapy -- Chapter 16 The challenge to Overcome Triple Negative Breast Cancer Heterogeneity -- Chapter 17 Surgical Management of Breast Cancer after Preoperative Systemic Treatment -- Chapter 18 Imaging of Tumor Response by Preoperative Systemic Treatment -- Part VI Preoperative anti-HER2 therapy -- Chapter 19 Human Epidermal Growth Factor Receptor (HER) Family Molecular Structure -- Chapter 20 Locoregional Therapy Following Neoadjuvant Therapy for HER2-Positive Breast Cancer: Opportunities and Challenges -- Part VII Mathematical prediction/assessment model -- Chapter 21 Nomograms to predict positive resection margin and to predict 3 or more positive lymph nodes -- Chapter 22 Practical Use of Nomograms -- Chapter 23 Data Mining and Mathematical Model Development.
520			_aThis book deals with the essential factors in the personalization of treatment for primary breast cancer. These include host issues, lymph node surgery, radiation therapy, and preoperative systemic treatment requiring specialized knowledge, multidisciplinary care experience, techniques, and research. Locoregional treatment in conjunction with systemic treatments is another important factor, with options for local therapy significantly affected by genetic BRCA mutation. Axillary treatment issues have become top priorities in recent primary breast cancer care, and these are highlighted in the book�s presentation of technological advances in lymph node mapping and diagnosis, axillary clearance in patients with nodal metastasis, and the role of axillary surgery. Attention is also given to locoregional treatment after preoperative systemic therapy. Because therapeutic impact differs depending upon biological characteristics such as tumor subtype, local therapy should be based both on tumor biology and on therapeutic response in parallel. Associated translational research and mathematical prediction tools such as nomograms also are introduced. This book provides the essence of primary breast cancer care, particularly its individualization with novel therapeutic concepts and strategies, and will greatly benefit physicians and clinical investigators in breast cancer institutions.
650		7	_aCerebro _xTumores _9214753
700	1		_aBenson, John. _eeditor literario _92295 _0comprobar BNE19922703147 _0http://id.loc.gov/authorities/names/n2015049955 _1http://viaf.org/viaf/12359831
700	1		_aKlimberg, Suzanne _eeditor literario _0Local _0http://id.loc.gov/authorities/names/n99803174 _9100387
700	1		_aToi, Masakazu. _eeditor literario _9100384 _0Local _0http://id.loc.gov/authorities/names/n2010184777 _1http://viaf.org/viaf/160949747
700	1		_aWiner, Eric. _eeditor literario _9100386 _0Local _1http://viaf.org/viaf/65499505
710	2		_aSpringerLink (Online service) _0Local _0http://id.loc.gov/authorities/names/no2005046756 _1http://viaf.org/viaf/148105729 _9106996
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-4-431-55552-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9784431555520
907			_a.b12958475 _b10-10-17 _c21-11-16
942			_2lcc _cLE
945			_aEBOOK EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11615801 _z30-06-17
988			_aSpringer_Medicine_2016
998			_aSI _a_alco _a_vill _b10/2018 _cm _dz _ef _feng _gja _h0
999			_c86569 _d86569 _x1